FANGZHOU JIANKE (06086), a leading player in the AI-driven chronic disease management sector, saw its stock price surge by 9.12% in intraday trading. The significant uptick comes on the heels of the company's impressive 2025 interim results and its strategic advancements in AI technology, which have caught the attention of investors and market analysts alike.
The company's financial performance has been particularly noteworthy, with revenue reaching approximately RMB 1.494 billion in the first half of 2025, marking a 12.9% year-on-year increase. More impressively, FANGZHOU JIANKE has turned the corner on profitability, reporting a net profit of RMB 12.5 million, a stark contrast to its previous losses. The adjusted net profit also saw a robust 16.8% year-on-year growth, reaching RMB 17.6 million. These figures underscore the company's successful transition into a profit-generating phase, validating its business model and growth strategy.
Investors are particularly enthused by FANGZHOU JIANKE's strategic positioning in the AI and chronic disease management space. The company has made significant strides in integrating AI technology into its operations, launching innovative solutions such as the "AI Electronic Medical Record (EMR) Agent" and "AI Pre-consultation Agent". These AI-driven tools, coupled with the company's "familiar doctor-patient" model, have created a unique ecosystem that sets FANGZHOU JIANKE apart in the competitive healthcare technology landscape. The potential for AI to revolutionize chronic disease management, coupled with favorable government policies and growing market demand, positions the company for substantial future growth.
As FANGZHOU JIANKE continues to leverage its AI capabilities and strengthen its market position, analysts remain bullish on its prospects. With Citi initiating coverage with a "Buy" rating and a target price of HK$8.5, the stock's current surge may be just the beginning of a longer-term upward trajectory, reflecting the market's growing recognition of the company's value proposition in the rapidly evolving healthcare technology sector.